SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 216 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.76 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2018 | $425,000 | +11.0% | 7,100 | -15.2% | 0.13% | +1.6% |
Q1 2018 | $383,000 | -1.5% | 8,370 | -14.2% | 0.13% | 0.0% |
Q4 2017 | $389,000 | -5.6% | 9,760 | -5.2% | 0.13% | -5.9% |
Q3 2017 | $412,000 | -54.9% | 10,290 | -51.5% | 0.14% | -47.9% |
Q2 2017 | $914,000 | -6.3% | 21,214 | -31.9% | 0.26% | +12.5% |
Q1 2017 | $975,000 | +24.0% | 31,141 | 0.0% | 0.23% | +28.9% |
Q4 2016 | $786,000 | +0.1% | 31,141 | -1.9% | 0.18% | -3.2% |
Q3 2016 | $785,000 | -43.2% | 31,741 | -53.2% | 0.19% | -48.0% |
Q2 2016 | $1,383,000 | +158.0% | 67,881 | +93.3% | 0.36% | +109.4% |
Q1 2016 | $536,000 | +18.1% | 35,125 | +4.0% | 0.17% | +18.8% |
Q4 2015 | $454,000 | -10.3% | 33,790 | -6.3% | 0.14% | -12.7% |
Q3 2015 | $506,000 | -51.2% | 36,060 | -40.9% | 0.16% | -47.3% |
Q2 2015 | $1,036,000 | +40.6% | 60,990 | 0.0% | 0.31% | +39.7% |
Q1 2015 | $737,000 | +120.0% | 60,990 | +51.0% | 0.22% | +88.2% |
Q4 2014 | $335,000 | – | 40,380 | – | 0.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
S&T BANK/PA | 215,578 | $5,943 | 1.15% |
Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |